Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

(2016) Tsukasa Ito-Horiyama et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fosfomycin

(2016) Matthew E. Falagas et al.   CLINICAL MICROBIOLOGY REVIEWS

The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?

(2016) Matthew E. Falagas et al.   Expert Review of Anti-Infective Therapy

In VitroAntimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

(2015) Naoki Kohira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria

(2015) Akinobu Ito et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections

(2014) Matthew E. Falagas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis

(2013) Ioanna P Korbila et al.   Expert Review of Anti-Infective Therapy

Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysis

(2012) Matthew E. Falagas et al.   CLINICAL INFECTIOUS DISEASES

Effectiveness and Safety of Tigecycline: Focus on Use for Approved Indications

(2012) K. Z. Vardakas et al.   CLINICAL INFECTIOUS DISEASES

Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: The study, the patient, the bug or the drug?

(2012) Konstantinos Z. Vardakas et al.   JOURNAL OF INFECTION